Dianthus Therapeutics (Dianthus Therapeutics) Long-Term Capital Lease Obligation : $0.10 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Long-Term Capital Lease Obligation?

Dianthus Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.10 Mil.

Dianthus Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($0.26 Mil) to Dec. 2023 ($0.17 Mil) and declined from Dec. 2023 ($0.17 Mil) to Mar. 2024 ($0.10 Mil).

Dianthus Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.44 Mil) but then declined from Dec. 2022 ($0.44 Mil) to Dec. 2023 ($0.17 Mil).

Dianthus Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Dianthus Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Long-Term Capital Lease Obligation Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

0.44

0.17

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial			0.44	-	0.26	0.17	0.10

Dianthus Therapeutics (NAS:DNTH) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Dianthus Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023